Business
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
U.S. Losartan market totals $245M annually with 71M prescriptions COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, and Blink Rx LLC (“BlinkRx”), one of the most advanced patient access p
About this update from Scienture Holdings, Inc.
[{"type":"image","alt":"Scienture Holdings, Inc.","displaySize":"","headline":null,"caption":"Scienture Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":51,"url":"https://media.zenfs.com/en/globenewswire.com/28b8170836e8ea967b4f044154f8d636"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/13RYlt0th1D5Rsmp1JUGQA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/28b8170836e8ea967b4f044154f8d636","width":300,"height":51}},"lazy":false},{"type":"text","content":"U.S. Losartan market totals $245M annually with 71M prescriptions ","length":65,"tagName":"p"},{"type":"text","content":"COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, and Blink Rx LLC (“BlinkRx”), one of the most advanced patient access platforms for branded medications, today announced a strategic collaboration to expand national access to Arbli™, the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Arbli™ is expected to be available on the BlinkRx platform in Q1 2026.","length":705,"tagName":"p"},{"type":"text","content":"BlinkRx holistically orchestrates and automates patient access, support, and delivery across the entire prescription journey. Its platform not only improves accessibility but also elevates the patient experience and drives meaningful health outcomes. With BlinkRx, 52% more patients start therapy and remain on their medication 40% longer as prescribed.","length":353,"tagName":"p"},{"type":"text","content":"According to IQVIA data (MAT September 2025), the U.S. losartan market totals approximately $245 million in annual sales, with over 71 million prescriptions written each year. With Arbli™, Scienture is positioned to address this significant commercial opportunity while fulfilling an unmet need for millions of patients requiring alternative dosage formats.","length":357,"tagName":"p"},{"type":"text","content":"“Arbli™ represents a meaningful advancement for patients who need a ready-to-use oral suspension of losartan potassium,” co...